澳洲非專利藥品的機會及課題 是由出版商Espicom Business Intelligence在2008年03月所出版的。
這份英文市場調查報告書包含Pages: 74 價格從美金865起跳。
澳洲的非專利藥品市場有14億3,000萬美元的規模，佔整體藥品市場的14.9%。
本報告書內容包括：澳洲國家資料及醫療制度概要、非專利藥品市場的動向、未來預測、主要企業等。內容綱要摘記如下：
序文
實施概要
市場背景資料
- 地理
- 澳洲地圖
- 政治概要
- 經濟概要
- 人口統計
- 澳洲的醫療制度
澳洲的非專利藥品市場
- 澳洲的藥品市場
- 非專利藥品的市場規模及預測
- PBS市場的非專利藥品
- 對藥品的管制規範
- 澳洲的生物學名藥
- 主要製造業者及供應商
- 價格及償付
- 患者自費負擔比率上昇：2005年
- 治療團體別保險費
- 美國的自由貿易協定
- 針對新加入企業的１2.5%價格下降
- 政府改革：2006年
智慧財產
藥品銷售
附錄1：國際比較
附錄2：資料來源
附錄3：匯率
Abstract
This report provides a complete assessment of the US$1.43 billion Australian
generic pharmaceutical market.
Valued at US$1.43 billion, the Australian generics market accounts for 14.9%
of the total pharma market value but only 30% by volume. With the government
keen to keep drug costs down, and with a number of major branded products
losing patent protection the market is one of the safer opportunities in the
region. But how will the market grow and in what way?
The central challenge to the Australian drug industry is the government' s
continued pressure to keep prices low in an effort to rein in PBS expenditure.
The change of regime is unlikely to help and the new Labor government will, if
anything, be even stricter.
Generics are not exempt from this; price reforms will place heavy downward
pressure on the value of the market for generics. These began with the 12.5%
cuts in 2005, and will go on until at least 2012. The most significant cut is
likely to be the 25% reduction mooted for August 2008. These should have the
effect of boosting volumes while depressing revenues.
However, generics are widely used and well accepted among patients and
prescribers. Generic expenditure per capita is on a rough par with the
Netherlands or Switzerland. Patent expiries will continue to be the main
driver of value growth in the market.
Opportunities?
More importantly, generic dispensing is, as a % of the whole, relatively low
at 30% of total prescriptions. With price a big issue, and with the prospect
of generic competition on leading products (such as atorvastatin, Australia' s
leading product) then the opportunity for generic volumes is good - but will
values follow?
The generic industry is highly concentrated. Until recently, the only
significant player was Alphapharm, although its position at the top has come
under increasing threat from the new Sigma/Arrow partnership. The market is
becoming more open to overseas players, although they are as yet to take
significant market share. Sandoz, Ranbaxy and Teva all have established an
interest in the market.
Now you can easily evaluate the Australian generic drugs market
But who are the leading players and what are their strengths/weaknesses? What
barriers to market entry exist? Where are the best opportunities? What is the
operating and regulatory environment for companies? The answers to these and
many other questions can be found in this 74-page report
Table of Contents
FOREWORD
EXECUTIVE SUMMARY
BACKGROUND TO THE MARKET
- Geography
- Map of Australia
- Political Overview
- Economic Overview
- Estimated/Projected GDP, 2007-2012
- Demographics
- Population
- Population, June 1995-2006
- Population by State/Territory, June 2006 (000s)
- Principal Demographic Indicators
- Principal Demographic Indicators, 1998-2005
- The Australian Healthcare System
- Organisation
- Commonwealth level
- State/Territory & Local Governments
- Healthcare expenditure
- Total Health Expenditure by Source of Funding, 1998/99 - 2004/05 (A$
millions)
- Total Health Expenditure by Type, 2001/02 - 2004/05 (A$ millions)
- Total Health Spending by Type & Source, 2004/05 (A$ millions)
- Health Expenditure by State/Territory, 1998/99 - 2004/05
- Hospitals
- Public/Private Hospitals, 1998/99 - 2004/05
- Private/Public Hospitals by State/Territory, 2004/05
- Public/Private Hospital Beds, 1998/99 - 2004/05
- Public/Private Beds by State/Territory, 2004/05
- Ambulatory Care
- Non-Admitted Patient Occasions of Service, Public Acute Hospitals,
1998/99-2004/05
- Medical personnel
- Medical Practitioners, 1998-2004
- Medical Practitioners by State/Territory, 2001-04
- Medical Specialists, 2002-04
THE AUSTRALIAN GENERIC PHARMACEUTICAL MARKET
- In Context: the Australian Pharmaceutical Market
- Summary of the Australian Pharmaceutical Market in 2007
- Market Projections, 2007-2012
- Pharmaceutical Expenditure by Source of Funds, 2003/04 - 2005/06 (A$
millions)
- Percentage Change in Pharmaceutical Expenditure, 1999/00 - 2005/06
- PBS prescription data
- PBS Prescriptions, 2001-06 (000s)
- Government Cost of PBS Prescriptions, 2001-06 (A$ millions)
- PBS Prescriptions by ATC Category, 2001-06 (000s)
- Total Cost of PBS Prescriptions by ATC Category, 2001-06 (A$ millions)
- Top 20 PBS Drugs by Volume, 2004-06
- Top 20 PBS Drugs by Cost, 2006 (A$ millions)
- Top 20 Suppliers to the PBS by Value, 2005/06
- Top 20 Suppliers to the PBS by Volume, 2005/06
- Top 20 Suppliers to the PBS by Volume, 2005/06
- Generic Market Size & Projections
- Projected Generic Market, 2006-2012 (A$ millions)
- Projected Generic Market, 2006-2012 (US$ millions)
- Summary Outlook
- Generics in the PBS Market
- PBS Data for leading Generic Manufacturers, 2005/06
- PBS Data for leading Generic Manufacturers, 2005/06 (% of Total)
- Discounting, Mark-ups and Average Price, 2005/06
- Discounting, Mark-ups and Average Price, 2005/06
- Pharmaceutical Regulation
- International harmonisation
- Biosimilars in Australia
- Omnitrope
- EU regulations adopted, 2006
- Mayne Pharma
- Leading Manufacturers & Suppliers
- Summary of Suppliers to the Australian Generic Market, 2007
- Alphapharm Pty Limited
- Financials
- Alphapharm Sales, 2000-06 (million euros)
- Alphapharm PBS Data, 2000-06
- Products
- Alphapharm Drugs Listed on the PBS, January 2008
- US presence
- Alphapharm US FDA ANDA Approvals 2002-07
- Arrow Pharmaceuticals Pty Ltd
- Financials
- Arrow PBS Sales Data, 2005/06
- Products
- Arrow Prescription Drug Products (home developed), 2007
- Arrow Drugs Listed on the PBS, January 2008
- Aspen Australia
- Financials
- Aspen Pharmacare, Australian Sales Results, 2006-07 (million Rand)
- Products
- Aspen signs distribution deal with Teva
- Genepharm Pty Ltd
- Financials
- Genepharm Australasia Financial Results, 2006/07 (A$ millions)
- Products
- Genepharm Drugs Listed on the PBS, January 2008
- Supply agreements
- Generic Health Pty Ltd/Bellwether Pharma
- Products
- Bellwether Pharma Drugs Listed on the PBS, January 2008
- GenRx Pty Ltd
- GenRx PBS Sales Data, 2005/06
- Products
- GenRx Drugs Listed on the PBS, January 2008
- Mayne Pharma (Hospira)
- Financials
- Mayne Financial Results, Fiscal 2005-06
- Sales by Category, 2006
- Mayne Pharma PBS Sales, 2003/04 - 2005/06
- Products
- Leading Mayne Pharma Products, August 2006
- Mayne Pharma Drugs Listed on the PBS, January 2008
- US presence
- Mayne Pharma ANDA approvals, 2002-07
- Faulding Pharmaceutical ANDA approvals, 2002-03
- PharmAust
- Ranbaxy Australia Pty Limited
- Products
- Ranbaxy Australia Drugs Listed on the PBS, January 2008
- Sandoz Pty Ltd
- Hexal Australia, PBS Sales 2005/06
- Products
- Sandoz Drugs Listed on the PBS, January 2008
- Sigma Pharmaceuticals (Australia) Pty Ltd
- Products
- Sigma Drugs Listed on the PBS, January 2008
- Orphan Pharmaceuticals
- Winthrop Pharmaceuticals
- Products
- Winthrop Drugs Listed on the PBS, January 2008
- Pricing & reimbursement: PBS
- Selected Generic Medicine Price Comparisons, November 2004 (A$)
- Rise in Co-payment rates, 2005
- Therapeutic Group Premiums
- US Free Trade Agreement
- 12.5% price reductions for new market entrants
- Government announces further PBS reforms, 2006
- Intellectual property
- Data exclusivity
- ' Springboarding'
- US Free Trade Agreement, Generic Amendments
- Ranbaxy fails to overturn patent on Lipitor
- Pharmaceutical distribution
- Wholesaling
- Top Three Wholesalers, Pharmacy Revenues 2006-07 (A$ millions)
- National Pharmaceutical Services Association
- Australian Pharmaceutical Industries Ltd (API)
- Sigma Pharmaceuticals
- Symbion Health (formerly Mayne Group)
- Retailing
- Community Pharmacies by State/Territory, June 2007
- People per Pharmacy, June 2007
- New wholesaler/pharmacy margin deal agreed
APPENDIX 1: INTERNATIONAL COMPARISONS
- Generic Pharmaceutical Expenditure
- Generic Pharmaceutical Expenditure, 2007 (US$ billions)
- Generic Pharmaceutical Expenditure per capita, 2007 (US$)
- Generic Pharmaceutical Expenditure as % of Total, 2007
APPENDIX 2: SOURCES
- Espicom Sources
- Australian Government Sources
- Industry Sources
APPENDIX 3: EXCHANGE RATES
|
